Previous Close | 0.0968 |
Open | 0.0902 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.0902 - 0.1000 |
52 Week Range | 0.0370 - 0.2750 |
Volume | |
Avg. Volume | 134,136 |
Market Cap | 6.904M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | 3.23 |
EPS (TTM) | 0.0310 |
Earnings Date | Oct 21, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, is pleased to announce that it has applied with the U.S. Food and Drug Administration (“FDA”) to receive Orphan Drug Designation (“ODD”) for ketamine to treat Rett Syndrome, a rare genetic neurological disorder. Ketamine has been subject to a Phase 2 clinical trial (NCT03633058) for Rett syndrome. Unpublished results from
Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA approvals for KETARX™ via the ANDA and 505(b)(2) regulatory pathways in H2-2023 Company aims to advance clinical development programs of KETARX™, including (i) Phase 3 clinical study for Parkinson’s disease; (ii) Phase 2 clinical study with microneedle patch; and (iii) Phase 2 clinical study for Amyotrophic lateral sclerosis Company granted 4 FDA orpha
PharmaTher’s 4th FDA orphan drug designation for ketamineTORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ketamine in the prevention of ischemia-reperfusion injury from organ transplantation. The Company currently holds four orphan drug designations granted by the FDA